ProPhase Labs to Participate in Virtual Investor Summit Microcap Event
GARDEN CITY, NY, -- ProPhase Labs, Inc. (NASDAQ: PRPH), a leader in biotech, genomics, and diagnostics, has announced its participation in the upcoming Virtual Investor Summit Microcap Event. This event will showcase a range of micro-cap companies that are on the brink of growth and innovation in today’s market. Throughout the day, ProPhase will hold one-on-one meetings, offering investors a valuable chance to connect with the company’s leadership team.
Event Information
Event: Q3 Investor Summit
Date: August 20, 2024
Presentation Time: 1:00 P.M. ET
Highlights of the Event
- Featuring 50 micro-cap companies with significant catalysts or impressive performance.
- Engaging discussions with leading investors in the MicroCap sector.
- Live Q&A sessions for direct interaction.
- Free access for qualified investors; registration is necessary.
About ProPhase Labs
ProPhase Labs Inc. (Nasdaq: PRPH) is at the cutting edge of biotechnology, genomics, and diagnostics, dedicated to creating a healthier world through innovative solutions. The company is transforming healthcare with its industry-leading Whole Genome Sequencing capabilities. Additionally, ProPhase is developing groundbreaking diagnostics and therapeutics aimed at fighting cancer.
One of their notable initiatives includes a potentially life-saving early detection test for esophageal cancer, underscoring ProPhase's commitment to advancing healthcare technology. Furthermore, they are exploring potential breakthrough cancer therapeutics that utilize novel mechanisms of action. ProPhase’s state-of-the-art CLIA laboratories, paired with agile diagnostic technology, empower healthcare providers and consumers with essential wellness solutions.
The company is committed to operational excellence, strategic diversification, and a synergistic multi-channel approach, all of which enhance its substantial growth potential. Through its valuable subsidiaries, ProPhase Labs demonstrates a strong business model aimed at transforming the health and wellness landscape.
Contact Information
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
Frequently Asked Questions
1. What is the Virtual Investor Summit Microcap Event?
The Virtual Investor Summit Microcap Event serves as a platform where micro-cap companies can present their business models and growth strategies to potential investors.
2. When is ProPhase Labs scheduled to present at the event?
ProPhase Labs is set to present on August 20, 2024, at 1:00 PM ET.
3. What are the main focus areas for ProPhase Labs?
ProPhase Labs specializes in biotechnology, genomics, and diagnostics, with a strong focus on cancer detection and therapeutic solutions.
4. How can investors interact with ProPhase Labs during the event?
Investors can interact with ProPhase Labs through one-on-one meetings and live Q&A sessions during the event.
5. What distinguishes ProPhase Labs' approach to healthcare?
ProPhase Labs utilizes advanced genome sequencing technology and innovative diagnostics to deliver cutting-edge healthcare solutions aimed at enhancing patient outcomes.